IL188357A0 - Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders - Google Patents
Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disordersInfo
- Publication number
- IL188357A0 IL188357A0 IL188357A IL18835707A IL188357A0 IL 188357 A0 IL188357 A0 IL 188357A0 IL 188357 A IL188357 A IL 188357A IL 18835707 A IL18835707 A IL 18835707A IL 188357 A0 IL188357 A0 IL 188357A0
- Authority
- IL
- Israel
- Prior art keywords
- mutants
- autoimmune disorders
- treat cancers
- cysteine
- truncated
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
- 235000018417 cysteine Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70095105P | 2005-07-20 | 2005-07-20 | |
| US77126006P | 2006-02-08 | 2006-02-08 | |
| PCT/US2006/028106 WO2007013944A2 (en) | 2005-07-20 | 2006-07-20 | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL188357A0 true IL188357A0 (en) | 2008-04-13 |
Family
ID=37683787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL188357A IL188357A0 (en) | 2005-07-20 | 2007-12-24 | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20070020227A1 (https=) |
| EP (1) | EP1909821A2 (https=) |
| JP (1) | JP4987001B2 (https=) |
| AU (1) | AU2006272937A1 (https=) |
| CA (1) | CA2616004A1 (https=) |
| IL (1) | IL188357A0 (https=) |
| WO (1) | WO2007013944A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927040B2 (en) * | 2000-06-30 | 2005-08-09 | Zymogenetics, Inc. | Interferon-like protein Zcyto21 |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| EP1927600A1 (en) | 2003-08-07 | 2008-06-04 | Zymogenetics, Inc. | Homogeneous preparations of IL-28 and IL-29 |
| JP2009502803A (ja) * | 2005-07-20 | 2009-01-29 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法 |
| CA2616004A1 (en) * | 2005-07-20 | 2007-02-01 | Zymogenetics, Inc. | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
| WO2007041713A1 (en) * | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
| JP2009115776A (ja) * | 2007-07-11 | 2009-05-28 | Ngk Spark Plug Co Ltd | アンモニアガスセンサ |
| JP5083898B2 (ja) * | 2007-07-11 | 2012-11-28 | 日本特殊陶業株式会社 | アンモニアガスセンサ |
| JP2011522834A (ja) * | 2008-06-05 | 2011-08-04 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用 |
| US20100316608A1 (en) * | 2009-06-15 | 2010-12-16 | Vijayaprakash Suppiah | Method of Determining A Response To Treatment With Immunomodulatory Composition |
| FR2975185A1 (fr) * | 2011-05-12 | 2012-11-16 | Univ Claude Bernard Lyon | Procede de determination in vitro de la presence d'une sclerose en plaques |
| CN104045704B (zh) * | 2013-03-11 | 2016-08-10 | 中国医学科学院基础医学研究所 | PEG化重组人IFN-λ1、其制备方法和用途 |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| CN103923209B (zh) * | 2014-05-13 | 2016-06-22 | 北京凯因科技股份有限公司 | 一种Lambda干扰素突变体及聚乙二醇衍生物 |
| CN105085658B (zh) * | 2014-05-14 | 2019-12-24 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体及聚乙二醇衍生物 |
| DE102015001902A1 (de) * | 2015-02-18 | 2016-08-18 | Continental Reifen Deutschland Gmbh | Verfahren zur Verbesserung der Haftung zwischen einem Verstärkungselement und einem elastomeren Matrixmaterial |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| WO2018064574A1 (en) * | 2016-09-30 | 2018-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Variant type iii interferons and synthekines |
| WO2021119749A1 (en) * | 2019-12-20 | 2021-06-24 | The Council Of The Queensland Institute Of Medical Research | Treatment of gastrointestinal disease |
| GB202003595D0 (en) * | 2020-03-12 | 2020-04-29 | Ilc Therapeutics Ltd | Compositions and methods relating to the treatment of diseases |
| KR102226826B1 (ko) * | 2020-08-06 | 2021-03-11 | 주식회사 휴벳바이오 | 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE54096B1 (en) | 1980-01-08 | 1989-06-21 | Biogen Nv | Dn sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides |
| US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US6468776B1 (en) * | 2000-03-03 | 2002-10-22 | Zymogenetics, Inc. | Human serine protease |
| US6927040B2 (en) * | 2000-06-30 | 2005-08-09 | Zymogenetics, Inc. | Interferon-like protein Zcyto21 |
| US6822082B2 (en) * | 2000-06-30 | 2004-11-23 | Zymogenetics, Inc. | Polynucleotides for mammalian secreted protein, Z1055G2P |
| JP2004509617A (ja) | 2000-09-08 | 2004-04-02 | シェーリング コーポレイション | 哺乳動物遺伝子；関連試薬および方法 |
| EP1942187B1 (en) * | 2001-04-20 | 2010-09-22 | ZymoGenetics, L.L.C. | Cytokine protein family |
| US7038032B2 (en) * | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| WO2002092762A2 (en) * | 2001-05-10 | 2002-11-21 | Immunex Corporation | Cytokine polypeptides |
| WO2003066002A2 (en) * | 2002-02-08 | 2003-08-14 | University Of Medicine And Dentistry Of New Jersey | IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION |
| EP2295455A1 (en) | 2002-04-19 | 2011-03-16 | ZymoGenetics, L.L.C. | Cytokine receptor |
| EP1575609A4 (en) | 2002-10-23 | 2010-12-15 | Zymogenetics L L C | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29 |
| EP1927600A1 (en) * | 2003-08-07 | 2008-06-04 | Zymogenetics, Inc. | Homogeneous preparations of IL-28 and IL-29 |
| WO2005097165A2 (en) | 2004-04-02 | 2005-10-20 | Zymogenetics, Inc. | Il-28 and il-29 cysteine mutants for treating viral infection |
| CA2574564C (en) * | 2004-07-29 | 2013-04-16 | Zymogenetics, Inc. | Use of il-28 and il-29 to treat cancer and autoimmune disorders |
| CN1305902C (zh) | 2004-11-25 | 2007-03-21 | 汕头大学医学院 | 一种人白细胞介素29的生产方法及重组il－29工程菌 |
| CA2616004A1 (en) * | 2005-07-20 | 2007-02-01 | Zymogenetics, Inc. | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
| JP2009502803A (ja) * | 2005-07-20 | 2009-01-29 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法 |
| WO2007041713A1 (en) * | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
-
2006
- 2006-07-20 CA CA002616004A patent/CA2616004A1/en not_active Abandoned
- 2006-07-20 WO PCT/US2006/028106 patent/WO2007013944A2/en not_active Ceased
- 2006-07-20 AU AU2006272937A patent/AU2006272937A1/en not_active Abandoned
- 2006-07-20 EP EP06787912A patent/EP1909821A2/en not_active Withdrawn
- 2006-07-20 US US11/489,894 patent/US20070020227A1/en not_active Abandoned
- 2006-07-20 JP JP2008522947A patent/JP4987001B2/ja active Active
-
2007
- 2007-12-24 IL IL188357A patent/IL188357A0/en unknown
-
2009
- 2009-11-02 US US12/611,067 patent/US20100298230A1/en not_active Abandoned
-
2011
- 2011-03-07 US US13/042,210 patent/US8313739B2/en active Active
-
2012
- 2012-04-05 US US13/440,066 patent/US20120251488A1/en not_active Abandoned
-
2013
- 2013-08-22 US US13/973,127 patent/US20140044676A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1909821A2 (en) | 2008-04-16 |
| US8313739B2 (en) | 2012-11-20 |
| US20100298230A1 (en) | 2010-11-25 |
| WO2007013944A3 (en) | 2007-05-18 |
| CA2616004A1 (en) | 2007-02-01 |
| WO2007013944A2 (en) | 2007-02-01 |
| AU2006272937A1 (en) | 2007-02-01 |
| JP4987001B2 (ja) | 2012-07-25 |
| US20120251488A1 (en) | 2012-10-04 |
| US20140044676A1 (en) | 2014-02-13 |
| JP2009502800A (ja) | 2009-01-29 |
| US20070020227A1 (en) | 2007-01-25 |
| AU2006272937A8 (en) | 2008-02-28 |
| US20110177024A1 (en) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL188357A0 (en) | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders | |
| IL190187A0 (en) | Antibody-drug conjugates and methods of use | |
| IL180589A0 (en) | Use of il-28 and il-29 to treat cancer and autoimmune disorders | |
| IL190733A0 (en) | Methods and compositions for use in treatment of patients with autoantibody positive diseases | |
| SI1835924T1 (sl) | Zdravljenje Parkinsonove bolezni in sorodnih obolenj z uporabo celic, pridobljenih post partum | |
| IL188420A0 (en) | Methods and compositions with enhanced therapeutic activity | |
| EP1827362A4 (en) | COMPOSITIONS AND METHODS OF USE FOR IMPROVING THE STATE AND THE APPEARANCE OF THE SKIN | |
| PL3398606T3 (pl) | Kompozycje otrzymane z mikroalg poprawiające zdrowie i wygląd skóry | |
| IL189602A0 (en) | Indenoisoquinolinone analogs and methods of use thereof | |
| ZA200806114B (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
| ZA200803859B (en) | Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies | |
| EP1968607A4 (en) | TREATMENT OF CANCER AND OTHER DISEASES | |
| IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| IL182222A0 (en) | Treatment of bipolar disorders and associated symptoms | |
| GB2421212B (en) | Cover skin with high and low gloss | |
| EP1703907A4 (en) | COMPOSITIONS AND METHODS FOR TREATING RECURRENT CONDITIONS | |
| EP1931390A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES | |
| EP1786265A4 (en) | NEW COMPOSITIONS AND PROCESSING METHODS | |
| EP1733045A4 (en) | DESIGN AND THERAPEUTIC USE OF ADPASE-ENHANCED APYRASES | |
| EP1601348A4 (en) | Compositions and methods with improved therapeutic activity | |
| EP1848806A4 (en) | ANTI-T CELL AND AUTOANTIGEN TREATMENT OF AN AUTOIMMUNE DISEASE | |
| GB0420789D0 (en) | Methods relating to generation of identities and authentication thereof | |
| EP1881987A4 (en) | PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | |
| AU2003263988A8 (en) | Methods and compositions to treat conditions associated with neovascularization | |
| GB0604826D0 (en) | The treatment of inflammatory disorders and pain |